10,421 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by AG2R LA Mondiale Gestion D Actifs

Key Points

• AG2R LA Mondiale Gestion D Actifs has acquired a new position in Zimmer Biomet Holdings, purchasing 10,421 shares valued at approximately $1,179,000.
• Zimmer Biomet reported a quarterly EPS of $2.07, exceeding analysts' expectations and indicating a 7.0% revenue increase year-over-year.
• The company announced a quarterly dividend of $0.24 to be paid on October 31st, representing an annualized yield of 0.9%.

AG2R LA Mondiale Gestion D Actifs bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm bought 10,421 shares of the medical equipment provider's stock, valued at approximately $1,179,000.

A number of other institutional investors have also bought and sold shares of ZBH. Brighton Jones LLC purchased a new position in Zimmer Biomet in the 4th quarter worth approximately $204,000. Focus Partners Wealth lifted its stake in Zimmer Biomet by 16.2% in the 4th quarter. Focus Partners Wealth now owns 16,528 shares of the medical equipment provider's stock worth $1,760,000 after purchasing an additional 2,303 shares in the last quarter. OMERS ADMINISTRATION Corp lifted its stake in Zimmer Biomet by 19.9% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 8,684 shares of the medical equipment provider's stock worth $917,000 after purchasing an additional 1,443 shares in the last quarter. Nomura Holdings Inc. purchased a new position in Zimmer Biomet in the 4th quarter worth approximately $693,000. Finally, Mufg Securities Americas Inc. purchased a new position in Zimmer Biomet in the 4th quarter worth approximately $310,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. UBS Group raised their target price on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a research note on Friday, August 8th. Evercore ISI reduced their price target on shares of Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a research report on Tuesday, July 8th. Roth Capital reaffirmed a "buy" rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Raymond James Financial lifted their price target on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Finally, Royal Bank Of Canada lifted their price target on shares of Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Nine analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $111.00.

Zimmer Biomet Stock Down 1.1%

Shares of NYSE ZBH opened at $103.15 on Friday. The firm has a market cap of $20.43 billion, a price-to-earnings ratio of 25.10, a PEG ratio of 2.40 and a beta of 0.68. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $114.72. The business's 50 day moving average is $99.46 and its two-hundred day moving average is $99.55.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. The company had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet's payout ratio is presently 23.36%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the business's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president owned 6,833 shares of the company's stock, valued at $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.39% of the stock is currently owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.